宜宾鼻子玻尿酸一针宜宾开发区眼部除皱价格,宜宾鼻尖线雕,宜宾两只眼睛割双眼皮多少钱,宜宾脱毛美容医院,宜宾医院做双眼皮手术,宜宾那个切双眼皮医院好,宜宾哪个割双眼皮医院最好

The showdown over mail-in ballots is expected to heat up this week.Democrats are calling back Congress to vote on legislation to prevent the U.S. Postal Service from changing any of its operations. A House committee also called an emergency hearing for next week to address mail delays and concerns the White House is interfering.The USPS is removing hundreds of mail processing machines across the country and has warned 46 states that it may not be able to process all mail-in ballots in time to be counted for the election.“Are we going to force people to have to choose between their fundamental right to vote and their health?” asked Shaundra Scott with the South Carolina Democratic Party. “The American voters are going to be very frustrated that we may not know who the winner is until frankly December.”Political experts agree the presidential race, pandemic and mail-in voting will all lead to massive increases in voter turnout and probably a lot of contested results.Some states have streamlined mail-in and absentee voting for years. However, other states are rushing to change their voting process because of the pandemic.“When things like that happen, it doesn't inspire confidence. It leads to the fear that people who shouldn't be voting may potentially be voting or people that should vote are not going to get ballots because of a snafu,” said Matt Klink, a GOP strategist with Klink Campaigns.For example, New York changed the rules to make it easier to vote by mail ahead of the primary, and it provided pre-paid envelopes. But those envelopes were not postmarked, or they were returned late. And there were other issues like ballots that weren't signed. That led to one out of four mail-in ballots being disqualified.But voting by mail could close the gap on inequities.“Yes, there are rules and regulations that say your employer should give you two hours to be able to vote but if you’re working hourly and you’re working on a job that is shift based, even though voting is extremely important, taking away that two hours of pay from someone and them having to make that decision is huge,” said Scott.Some expert say Republicans fear mail-in ballots would capture new Democratic voters, but seniors also benefit from absentee and mail-in voting. They often skew red, according to the Brookings Institute.A major study of California, Utah, and Washington state's elections between 1996 and 2018 found there was no partisan advantage to voting by mail. 2482

The service academy game between Air Force and Army scheduled for Saturday at West Point, New York, was postponed Thursday due to an increase in COVID-19 cases at the Air Force Academy and the surrounding community."We are disappointed to postpone this game, but the health and safety of our cadets, staff, and the community continues to be our No. 1 priority at the Academy," Air Force Falcons Director of Athletics Nathan Pine said in a press release. "Due to the upward trends in our COVID numbers across the campus, we have paused all intercollegiate team activities."The Falcons can win the Commander-in-Chief’s Trophy with a win over Army. Air Force began the round-robin competition between the service academies with a 40-7 win over Navy on Oct. 3.The winning academy goes to the White House to receive the coveted trophy from the President.According to The Athletic's Stewart Mandel, this marks the seventh college football game this week to be postponed or canceled due to COVID.The schools are working to reschedule the game. 1044

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The Trump campaign has dropped a central part of its lawsuit that seeks to delay the certification of election results in Pennsylvania, the state which proved to be the tipping point for Joe Biden in clinching the presidency.On Sunday, the Trump campaign dropped a portion of a lawsuit that alleged that more than 600,000 mail-in and absentee ballots were processed without Republican poll-watchers present. The claim has been a central part of President Donald Trump's argument that the 2020 election has been beset by widespread voter fraud.The Trump campaign's lawsuit now only focuses on claims that Republicans were "illegally disadvantaged" because some voters in Democratic-leaning counties were afforded the ability to fix mistakes on their mail-in ballots, a process called "curing." The Washington Post reports that the issue would likely only affect a small number of votes.Ballot curing is a process that takes place in several states. According to The Associated Press, there is no provision in Pennsylvania state law that prevents counties from affording voters the opportunity to cure ballots.Biden currently holds a lead of about 70,000 votes over Trump, with nearly all of the votes counted.Despite his campaign's altered lawsuit, Trump on Sunday continued to claim on Twitter — without providing evidence — that poll watchers "were thrown out of vote counting rooms in many of our States."Late Sunday evening, Trump tweeted, "I WON THE ELECTION!" a claim that quickly prompted Twitter to add a clarification to his message clarifying that "official sources have called this election differently." 1622

The stock market continued a September slide Monday, with the Dow Jones Industrial Average falling about 800 points at one point. The S&P 500 sank 1.2%, though a last-hour recovery helped it more than halve its loss from earlier in the day.The Dow Jones Industrial Average fell 509.72, or 1.8%, to 27,147.70 after coming back from an earlier 942 point slide. The Nasdaq composite slipped 14.48, or 0.1%, to 10,778.80 after recovering from a 2.5% drop.Monday’s downward movement was seen across many sectors, and market watchers point to multiple reasons.Multiple media outlets are reporting about documents indicating major banks around the world potentially ignored red flags and allowed millions to be transferred by questionable companies or individuals. Stock prices for banks, including JP Morgan Chase, fell on Monday. Many are worried about a spike in coronavirus cases and potential new “waves” of the virus; the United Kingdom announced they are seeing a sharp increase in cases.The recent death of Supreme Court Justice Ruth Bader Ginsburg and subsequent announcement a replacement could come soon means congress will be focused on hearings and the nomination process, and potentially not focused on any federal coronavirus relief aid, according to Marketplace.org.Without federal relief, economic experts have warned of a longer recovery. The Federal Reserve last week said the future of the U.S. economy remained uncertain.Over the weekend, China announced a new regulatory body that could blacklist foreign companies that put China’s national security at risk. NPR says this group could target U.S. tech companies operating in China, like Apple, Cisco, and others.Monday’s slide comes after a few weeks of stock market losses. September is historically the worst month for stocks, according to the Associated Press.“The market has been poised to just pull back, take a breather,” said Quincy Krosby, chief market strategist at Prudential Financial. “Raising capital is prudent during a month that is known statistically, historically for being difficult for the market.” 2095